 |
|
Overestimation of the Number of Individuals With Hypertension Who Are Eligible for Treatment According to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In a study by Lloyd-Jones et al,1 the impact of the recently published Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) on the number of subjects with hypertension who are eligible for treatment was estimated. Using data from the Framingham Heart Study, Lloyd-Jones et al estimated that according to the JNC-VI guidelines, 60.6% of the subjects in the high-normal or hypertensive group were eligible for initial drug therapy or were already receiving drug therapy. From the data that were presented in this study, it can be derived that 13.5% of the subjects in the high-normal or hypertensive group were eligible for initial pharmacological treatment.
The main conclusion from the discussion of the limitations of this study is that the number of individuals who are eligible for treatment may have been underestimated. One important limitation that was not discussed by Lloyd-Jones . . . [Full Text of this Article]
RELATED ARTICLE
Cross-classification of JNC VI Blood Pressure Stages and Risk Groups in the Framingham Heart Study
Donald M. Lloyd-Jones, Jane C. Evans, Martin G. Larson, Christopher J. O'Donnell, Peter W. F. Wilson, and Daniel Levy
Arch Intern Med. 1999;159(18):2206-2212.
ABSTRACT
| FULL TEXT
|
